Denmark's Novo Nordisk Announces Positive Trials For Stroke Drug

Denmark's Novo Nordisk, which specialises in therapies for blood-related disorders, has announced encouraging clinical trial results for new stroke therapy NovoSeven (recombinant coagulation factor VIIa), as published in The New England Journal of Medicine. The prospective drug is for acute intracerebral haemorrhage, a severe form of stroke with few existing treatment options. According to Novo Nordisk, the studies indicated a 16% absolute reduction in the risk of death or severe disability at three months, with a 38% fall in mortality relative to placebo.